A Long and Winding Road: Drug Development in Idiopathic Pulmonary Fibrosis.
作者信息
Spagnolo Paolo, Maher Toby M
机构信息
Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Department of Pulmonary, Critical Care and Sleep Medicine, University of Southern California Keck School of Medicine, Los Angeles, California; and.
出版信息
Am J Respir Crit Care Med. 2024 May 1;209(9):1072-1073. doi: 10.1164/rccm.202402-0290VP.
Abstract
摘要
相似文献
1
A Long and Winding Road: Drug Development in Idiopathic Pulmonary Fibrosis.一条漫长而曲折的道路：特发性肺纤维化的药物研发
Am J Respir Crit Care Med. 2024 May 1;209(9):1072-1073. doi: 10.1164/rccm.202402-0290VP.
2
"The Long and Winding Road" seeking specific drugs for idiopathic pulmonary fibrosis.《漫长而曲折的道路》：寻找特发性肺纤维化的特效药物
Respir Investig. 2016 Jan;54(1):1. doi: 10.1016/j.resinv.2015.12.001.
3
Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.特发性肺纤维化的药物发现与开发：挑战与机遇
Drug Discov Today. 2020 Dec;25(12):2277-2283. doi: 10.1016/j.drudis.2020.09.019. Epub 2020 Sep 30.
4
Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now.推进特发性肺纤维化的药物研发：未来已来。
Am J Respir Crit Care Med. 2024 May 1;209(9):1060-1062. doi: 10.1164/rccm.202402-0381ED.
5
What have we learned from basic science studies on idiopathic pulmonary fibrosis?特发性肺纤维化的基础科学研究给我们带来了什么启示？
Eur Respir Rev. 2019 Sep 11;28(153). doi: 10.1183/16000617.0029-2019. Print 2019 Sep 30.
6
Three wishes for improving clinical drug development in pulmonary fibrosis.改善肺纤维化临床药物研发的三个愿望。
Eur Respir J. 2023 Mar 2;61(3). doi: 10.1183/13993003.02355-2022. Print 2023 Mar.
7
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.获批疗法时代特发性肺纤维化临床试验的设计
Am J Respir Crit Care Med. 2019 Jul 15;200(2):133-139. doi: 10.1164/rccm.201903-0592PP.
8
Screening of Inhibitors Targeting Heat Shock Protein 47 Involved in the Development of Idiopathic Pulmonary Fibrosis.靶向热休克蛋白 47 治疗特发性肺纤维化的抑制剂筛选。
ChemMedChem. 2021 Aug 19;16(16):2515-2523. doi: 10.1002/cmdc.202100064. Epub 2021 May 19.
9
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.特发性肺纤维化：疾病机制与药物研发。
Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798. Epub 2020 Dec 24.
10
Shedding light on developmental drugs for idiopathic pulmonary fibrosis.揭示特发性肺纤维化治疗药物的研发进展。
Expert Opin Investig Drugs. 2020 Aug;29(8):797-808. doi: 10.1080/13543784.2020.1782885. Epub 2020 Jun 24.
引用本文的文献
1
Bleomycin promotes cellular senescence and activation of the cGAS-STING pathway without direct effect on fibrosis in an idiopathic pulmonary fibrosis model.在特发性肺纤维化模型中，博来霉素可促进细胞衰老和cGAS-STING途径的激活，而对纤维化无直接影响。
Aging (Albany NY). 2025 Aug 28;17(8):2189-2211. doi: 10.18632/aging.206312.
2
Integrative analysis of gene expression and chromatin dynamics multi-omics data in mouse models of bleomycin-induced lung fibrosis.博来霉素诱导的小鼠肺纤维化模型中基因表达与染色质动力学多组学数据的综合分析
Epigenetics Chromatin. 2025 Mar 12;18(1):11. doi: 10.1186/s13072-025-00579-5.
3
Targeting Autotaxin and Lysophosphatidic Acid in Pulmonary Fibrosis: Admilparant's Positive Results Show Continued Promise.靶向自分泌运动因子和溶血磷脂酸治疗肺纤维化：Admilparant的阳性结果显示出持续的前景。
Am J Respir Crit Care Med. 2025 Feb;211(2):148-150. doi: 10.1164/rccm.202410-2018ED.
4
Trigonelline hydrochloride attenuates silica-induced pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation.盐酸三叶草堿通过调控成纤维细胞向肌成纤维细胞分化来减轻二氧化硅诱导的肺纤维化。
Respir Res. 2024 Jun 15;25(1):242. doi: 10.1186/s12931-024-02876-1.
本文引用的文献
1
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.特发性肺纤维化（IPF）临床试验的有意义终点：强调“感觉、功能、生存”。在一次研讨会上的合作讨论报告，患者代表、研究者、美国国立卫生研究院、一个患者权益倡导组织和一个监管机构直接参与了此次研讨会。
Am J Respir Crit Care Med. 2024 Mar 15;209(6):647-669. doi: 10.1164/rccm.202312-2213SO.
2
External Control Arms in Idiopathic Pulmonary Fibrosis Using Clinical Trial and Real-World Data Sources.特发性肺纤维化中使用临床试验和真实世界数据源的外部控制臂。
Am J Respir Crit Care Med. 2023 Sep 1;208(5):579-588. doi: 10.1164/rccm.202210-1947OC.
3
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.采用基因型选择 NAC 治疗特发性肺纤维化的前瞻性疗效研究（PRECISIONS）的设计和原理。
BMC Pulm Med. 2022 Dec 13;22(1):475. doi: 10.1186/s12890-022-02281-8.
4
Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis.基于转录组数据集的聚类分析鉴定特发性肺纤维化的表型。
Thorax. 2023 Jun;78(6):551-558. doi: 10.1136/thoraxjnl-2021-218563. Epub 2022 May 9.
5
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
6
Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids.利用人多能干细胞衍生的肺泡类器官进行肺纤维化疾病建模。
Stem Cell Reports. 2021 Dec 14;16(12):2973-2987. doi: 10.1016/j.stemcr.2021.10.015. Epub 2021 Nov 18.
7
The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops.特发性肺纤维化的自我实现预言：病理性信号通路的选择性检查。
Eur Respir J. 2020 Nov 26;56(5). doi: 10.1183/13993003.00075-2020. Print 2020 Nov.
8
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.帕姆单抗，一种抗结缔组织生长因子疗法，用于特发性肺纤维化（PRAISE）：一项 2 期、随机、双盲、安慰剂对照试验。
Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28.
9
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.重组人 Pentraxin 2 与安慰剂对特发性肺纤维化患者用力肺活量变化的影响：一项随机临床试验。
JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.
10
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.GLPG1690 治疗特发性肺纤维化（FLORA）的安全性、耐受性、药代动力学和药效学：一项 2a 期随机安慰剂对照试验。
Lancet Respir Med. 2018 Aug;6(8):627-635. doi: 10.1016/S2213-2600(18)30181-4. Epub 2018 May 20.
Zotero 插件